Multimodal Machine Learning Characterization of Solid Tumors

Inclusion Criteria

• •Participants must meet the following criteria on screening examination to be eligible to participate in the study:
• •* Must have primary prostate cancer (e.g. adenocarcinoma of prostate) and deemed a candidate for radical prostatectomy as part of standard clinical care for Cohort A.
• •* Must have evidence or be suspected of having HCC, Glioma and RCC for enrollment in Cohort B.
• •* Age ≥18 years.
• •\--- Because no dosing or adverse event data are currently available on the use of \[18F\]DCFPyL in participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
• •* Participants must have adequate kidney function for gadolinium-based contrast administration as assessed by:
• •* estimated or measured glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2 for repeated administrations.
• •* a single dose will be administered to subjects with a GFR between 30-60 mL/min/1.73 m2. Investigators will not repeat the gadolinium-based contrast agent administration until the renal function improves and the GFR is higher than 60 cc/min/1.73 m2. These subjects will not undergo examinations on consecutive days even if the renal function improves.
• •Patient must be able to undergo MRI and PET scans.
• •Ability to understand and the willingness to sign a written informed consent document.